Key result
Trandolapril alone or combined with verapamil reduced proteinuria by 40.2% and 48.5% respectively in patients with primary renal disease.
Why the study?
Do different antihypertensive drugs have differing effects on proteinuria reduction in patients with primary renal disease when blood pressure is lowered to the same level?
RCT (n=119)
Double-blind
randomized
Yes
Do different antihypertensive drugs have differing effects on proteinuria reduction in patients with primary renal disease when blood pressure is lowered to the same level?
In patients with primary renal disease, ACE inhibitors alone or combined with non-dihydropyridine calcium channel blockers reduce proteinuria independently of blood pressure reduction, unlike beta-blockers.
Answers are grounded in this paper and cite their sources.
Supports ACEI or ACEI-verapamil regimens to reduce proteinuria beyond BP control in primary renal disease; confirms BP-independent effects unlike beta-blockers.
OBJECTIVE: Guidelines recommend lower threshold and goal blood pressure (BP) for patients with proteinuria. BP reduction could be accompanied by a different fall in proteinuria depending of the antihypertensive drug. The objective was to compare proteinuria reduction when BP is lowered to the same level with different drugs. DESIGN: Prospective, randomized, double-blind, controlled trial. SETTING: 12 Spanish centres. PATIENTS: A total of 119 patients with primary renal disease, blood pressure > 130/85 mmHg, proteinuria > 1 g/day, and creatinine clearance > or = 50 ml/min. INTERVENTION: After a 4-week run-in placebo period, patients were randomized to: atenolol 50 mg/day; trandolapril 2 mg/day; verapamil 240 mg/day or verapamil 180 + trandolapril 2 mg/day combination; forced double-dose titration was carried out at the 4th week. Treatment duration was 6 months. OUTCOME MEASURES: Changes in BP, 24 h proteinuria, serum albumin and calcium. RESULTS: BP was significantly reduced with the four treatments [SBP/DBP (mmHg]: atenolol 12.2/9.9; trandolapril 12.9/9.3; verapamil 8.2/7.9 and verapamil + trandolapril 13.6/11.3) without differences between them. A significant fall in proteinuria was seen in the trandolapril, 40.2% [95% confidence interval (CI) 24.3-56.2%], and verapamil + trandolapril groups, 48.5% (95% CI, 31.7-64.3%) accompanied with increases in serum albumin (trandolapril: from 3.86 +/- 0.64 to 4.03 +/- 0.67 g/dl; verapamil + trandolapril: from 4.15 +/- 0.58 to 4.40 +/- 0.51 g/dl). CONCLUSIONS: In patients with proteinuric primary renal disease, adequate dose titration of antihypertensive drugs may provide a substantial BP reduction. Only angiotensin-converting enzyme inhibitor (trandolapril) treatment, alone or better combined with verapamil, reduces proteinuria and increases serum albumin.
No takes yet. Share an insight, caveat, or question.
The PROCOPA Study Group (2002) conducted an RCT in primary renal disease (n=119). Trandolapril alone or combined with verapamil vs. Atenolol 50 mg/day or verapamil 240 mg/day was evaluated on Changes in BP, 24 h proteinuria, serum albumin and calcium (48.5% reduction in proteinuria for combination, 95% CI 31.7-64.3). Trandolapril alone or combined with verapamil reduced proteinuria by 40.2% and 48.5% respectively in patients with primary renal disease.
Synapse has enriched 10 related papers. Consider them for comparative context: